User menu

Osteoporosis assessment and treatment after hip or forearm fracture: a Belgian experience

Bibliographic reference Blondiaux, G. ; Devogelaer, Jean-Pierre ; Esselinckx, Walter ; Boutsen, Yves. Osteoporosis assessment and treatment after hip or forearm fracture: a Belgian experience.7th International Symposium on Osteoporosis (Washington (Dc), Apr 18-22, 2007). In: Osteoporosis International : with other metabolic bone diseases, Vol. 18, p. S59-S60 (2007)
Permanent URL
  1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785–795
  2. Looker AC, Johnston CC Jr, Wahner HW, Dunn WL, Calvo MS, Harris TB et al (1995) Prevalence of low femoral bone density in older U.S. women from NHANES III. J Bone Miner Res 10:796–802
  3. Looker AC, Orwoll ES, Johnston CC Jr, Lindsay RL, Wahner HW, Dunn WL et al (1997) Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res 12:1761–1768
  4. Jones CA, McQuillan GM, Kusek JW, Eberhardt MS, Herman WH, Coresh J et al (1998) Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis 32:992–999
  5. Klawansky S, Komaroff E, Cavanaugh PF Jr, Mitchell DY, Gordon MJ, Connelly JE et al (2003) Relationship between age, renal function and bone mineral density in the US population. Osteoporos Int 14:570–576
  6. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441
  7. Lu Y, Ye K, Mathur AK, Hui S, Fuerst TP, Genant HK (1997) Comparative calibration without a gold standard. Stat Med 16:1889–1905
  8. Lu Y, Mathur AK, Blunt BA, Gluer CC, Will AS, Fuerst TP et al (1996) Dual X-ray absorptiometry quality control: comparison of visual examination and process-control charts. J Bone Miner Res 11:626–637
  9. Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137–1148
  10. Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM et al (2005) Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 20:962–970
  11. Eastell R, Chen P, Krege JH (2005) Monitoring teriparatide therapy for osteoporosis with procollagen type I N-Propeptide (PINP). Curr Med Res Opin 22(1):61–68
  12. Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE (2005) Safety and efficacy of oral risedronate in patients with reduced renal function as assessed by the Cockcroft-Gault method: a pooled analysis from 9 clinical trials. J Bone Miner Res 20:2105–2115
  13. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41
  14. Food and Drug Administration, U. S. Department of Health and Human Services (1998) Guidance for industry. Pharmacokinetics in patients with impaired renal function-study design, data analysis, and impact on dosing and labeling. Available at . Accessed May 31, 2005
  15. Lindeman RD (1993) Assessment of renal function in the old. Special considerations. Clin Lab Med 13:269–277
  16. Ensrud KE, Palermo L, Black DM, Cauley J, Jergas M, Orwoll ES et al (1995) Hip and calcaneal bone loss increase with advancing age: longitudinal results from the study of osteoporotic fractures. J Bone Miner Res 10:1778–1787
  17. Krege JH, Donley DW, Marcus R (2005) Teriparatide, osteoporosis, calcium, and vitamin D. N Engl J Med 353:634–635
  18. US Forteo Prescribing Information (2004) Eli Lilly and Company, Indianapolis, IN, USA
  19. Miller Paul D., Bilezikian John P., Deal Chad, Harris Steven T., ci Roberto Pa, CLINICAL USE OF TERIPARATIDE IN THE REAL WORLD: INITIAL INSIGHTS, 10.4158/ep.10.2.139
  20. MASSRY SHAUL G., Skeletal Resistance to Parathyroid Hormone in Renal Failure : Studies in 105 Human Subjects, 10.7326/0003-4819-78-3-357
  21. Llach F, Massry SG, Singer FR, Kurokawa K, Kaye JH, Coburn JW (1975) Skeletal resistance to endogenous parathyroid hormone in patients with early renal failure. A possible cause for secondary hyperparathyroidism. J Clin Endocrinol Metab 41:339–345
  22. US Fosamax Prescribing Information (2004) Merck and Co., Whitehouse Station, NJ, USA
  23. US Actonel Prescribing Information (2004) Procter & Gamble Pharmaceuticals, Cincinnati, USA
  24. US Zometa Prescribing Information (2005) Novartis Pharmaceuticals, East Hanover, NJ, USA
  25. Lin J, Knight EL, Hogan ML, Singh AK (2003) A comparison of prediction equations for estimating glomerular filtration rate in adults without kidney disease. J Am Soc Nephrol 14:2573–2580
  26. Garg AX, Papaioannou A, Ferko N, Campbell G, Clarke JA, Ray JG (2004) Estimating the prevalence of renal insufficiency in seniors requiring long-term care. Kidney Int 65:649–653
  27. Lafayette RA, Perrone RD, Levey AS (1993) Laboratory evaluation of renal function. In: Schrier RW, Gottschalk CW (eds) Diseases of the kidney. Little, Brown and Company, Boston/Toronto/London, pp 333–370